Home LiteratureArticle Details
PMID: 22658126 Published · ppublish English Editorial Comment

Tumor immunotherapy directed at PD-1.

The New England journal of medicine ·Vol. 366 ·No. 26 ·2012-06-28 ·Pages 2517-9

Ribas A

Abstract

暂无摘要

MeSH Terms
Antibodies, Monoclonal/administration & dosage,therapeutic use Antineoplastic Agents/administration & dosage,therapeutic use Female Humans Male Neoplasms/drug therapy Nivolumab Programmed Cell Death 1 Receptor/antagonists & inhibitors
Chemicals
Antibodies, Monoclonal Antineoplastic Agents PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Ribas Antoni
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJMe1205943
Published
2012-06-28
Epub
2012-00-02
Pages
2517-9
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentOn
PMID: 22658127
CommentOn
PMID: 22658128
CommentIn
PMID: 22992095
External Links
PubMed source DOI: 10.1056/NEJMe1205943 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2